Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net revenues	$ 13,865	$ 14,583	$ 26,090	$ 28,121
Cost of products sold	4,240	4,170	8,226	8,222
Selling, general and administrative	3,268	5,412	6,307	8,539
Research and development	1,733	1,609	4,025	3,106
Acquired IPR&D and milestones	280	269	430	414
Other operating income	(169)	(172)	(179)	(172)
Total operating costs and expenses	9,352	11,288	18,809	20,109
Operating earnings	4,513	3,295	7,281	8,012
Interest expense, net	454	532	908	1,071
Net foreign exchange loss	37	47	72	72
Other expense, net	1,412	1,533	3,216	757
Earnings before income tax expense	2,610	1,183	3,085	6,112
Income tax expense	583	255	817	691
Net earnings	2,027	928	2,268	5,421
Net earnings attributable to noncontrolling interest	3	4	5	7
Net earnings attributable to AbbVie Inc.	$ 2,024	$ 924	$ 2,263	$ 5,414
Per share data
Basic earnings per share (in dollars per share)	$ 1.14	$ 0.52	$ 1.27	$ 3.04
Diluted earnings per share (in dollars per share)	$ 1.14	$ 0.51	$ 1.26	$ 3.03
Weighted-average basic shares outstanding (in shares)	1,767	1,770	1,768	1,770
Weighted-average diluted shares outstanding (in shares)	1,771	1,776	1,773	1,777